FDA approves Shire's triple-bead ADHD therapy

FDA approved Mydayis (SHP465) from Shire plc (LSE:SHP; NASDAQ:SHPG) to treat ADHD in patients aged 13 and older. The product consists of three-component, extended release, single-entity mixed amphetamine salts (MAS).

Shire plans to launch the drug in 3Q17. A Shire spokesperson told BioCentury the company will set Mydayis' price "in the coming week."...